Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 5/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL789030 | 0.90 | MEN1 (0.36) | MEN1KMT2AL3MBTL3L3MBTL1FPR2 | |
| SCHEMBL29249364 | 0.81 | ALDH1A1 (0.33) | MEN1KMT2AL3MBTL3L3MBTL1FPR2 | |
| SCHEMBL2456120 | 0.79 | FPR2 (0.50) | FPR2 | |
| SCHEMBL6968586 | 0.77 | L3MBTL1 (0.36) | L3MBTL1FPR2 | |
| SCHEMBL7516937 | 0.74 | MEN1 (0.37) | MEN1KMT2AFPR2 | |
| SCHEMBL18115882 | 0.72 | TGM2 (0.40) | KMT2AL3MBTL3L3MBTL1KDM5A | |
| SCHEMBL18115885 | 0.72 | TGM2 (0.40) | KMT2AL3MBTL3L3MBTL1KDM5A | |
| SCHEMBL29199110 | 0.72 | L3MBTL3 (0.36) | KMT2AL3MBTL3L3MBTL1KDM5A | |
| SCHEMBL789786 | 0.72 | FPR2 (0.55) | KMT2AFPR2 | |
| SCHEMBL23297156 | 0.71 | MEN1 (0.37) | MEN1KMT2AL3MBTL3L3MBTL1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | MEN1 2327/4885KMT2A 873/4885L3MBTL3 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.